Disappointing RethinQ Data Is Neither Plus Nor Minus For ICDs – Analysts
This article was originally published in The Gray Sheet
Executive Summary
The St. Jude-sponsored RethinQ trial will not expand the market for cardiac resynchronization therapy defibrillators as the company had hoped, but will not do further damage to the sluggish ICD market, analysts project